AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

Google DeepMind’s AlphaFold has transformed the scientific understanding of proteins, and now its drug design capabilities are set to be tested. Isomorphic Labs, a biotech spinoff from Google DeepMind, is preparing to start human trials of drugs developed using this AI technology. The company, founded in 2021, utilizes AlphaFold to predict protein structures, a task that was previously challenging due to the complexity of protein folding. AlphaFold’s advancements have been significant, with its latest version, AlphaFold 3, enhancing the understanding of proteins and their interactions with other molecules like DNA and RNA. This breakthrough has led to numerous scientific applications and earned its creators a Nobel Prize. Isomorphic Labs has also introduced IsoDDE, a new drug-design engine that improves upon AlphaFold 3’s accuracy. The company has partnered with Eli Lilly to further its research and development efforts. QUESTION: How might the success of AI-designed drugs in clinical trials change the future of medicine and healthcare?